| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Orexin 2 Receptor Agonist is a potent and selective Orexin2 receptor agonist with EC50 of 0.023 μM on OX2R; it is OX2R-selective (OX1R/OX2R EC50 ratio is 70). Orexin receptors 1 (OX1R) and 2 (OX2R) are two G-protein-coupled receptors that are the targets of the orexin family of neuropeptides, which controls sleep and wakefulness. Mechanistic therapy of the sleep disorder narcolepsy/cataplexy may benefit from the use of orexin receptor agonists, particularly OX2R agonist, according to genetic and pharmacologic evidence. The discovery of 4'-methoxy-N,N-dimethyl-3'-[N-(3-{[2-(3-methylbenzamido)ethyl]amino}phenyl)sulfamoyl] is reported here. It is a potent (EC50 on OX2R is 0.023 μM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist. -(biphenyl 1,1') 26-carboxamide -3.
| Targets |
OX2 Receptor
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
Orexin receptors 1 (OX1R) and 2 (OX2R) are two G-protein-coupled receptors that are the targets of the orexin family of neuropeptides, which controls sleep and wakefulness. Mechanistic therapy of the sleep disorder narcolepsy/cataplexy may benefit from the use of orexin receptor agonists, particularly OX2R agonist, according to genetic and pharmacologic evidence. The discovery of 4′-methoxy-N,N-dimethyl-3′-[N-(3-{[2-(3-methylbenzamido)ethyl]amino}phenyl)sulfamoyl] is reported herein as a potent (EC50 on OX2R is 0.023 μM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist. -(Biphenyl-1,1′) 26-carboxamide -3.
|
||
| Enzyme Assay |
Orexin 2 Receptor Agonist is an effective and specific Orexin2 receptor agonist that has an EC50 of 0.023 μM on OX2R. It is selective only for OX2R (EC50 ratio between OX1R and OX2R is 70). Orexin receptors 1 (OX1R) and 2 (OX2R) are two G-protein-coupled receptors that are the targets of the orexin family of neuropeptides, which controls sleep and wakefulness.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C32H34N4O5S
|
|
|---|---|---|
| Molecular Weight |
586.70
|
|
| Exact Mass |
586.224
|
|
| Elemental Analysis |
C, 65.51; H, 5.84; N, 9.55; O, 13.63; S, 5.46
|
|
| CAS # |
1796565-52-0
|
|
| Related CAS # |
|
|
| PubChem CID |
91810287
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Index of Refraction |
1.629
|
|
| LogP |
3.4
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
11
|
|
| Heavy Atom Count |
42
|
|
| Complexity |
986
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
S(C1C(=CC=C(C2C=CC=C(C(N(C)C)=O)C=2)C=1)OC)(NC1C=CC=C(C=1)NCCNC(C1C=CC=C(C)C=1)=O)(=O)=O
|
|
| InChi Key |
RHLMXWCISNJNDH-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C32H34N4O5S/c1-22-8-5-10-25(18-22)31(37)34-17-16-33-27-12-7-13-28(21-27)35-42(39,40)30-20-24(14-15-29(30)41-4)23-9-6-11-26(19-23)32(38)36(2)3/h5-15,18-21,33,35H,16-17H2,1-4H3,(H,34,37)
|
|
| Chemical Name |
N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7044 mL | 8.5222 mL | 17.0445 mL | |
| 5 mM | 0.3409 mL | 1.7044 mL | 3.4089 mL | |
| 10 mM | 0.1704 mL | 0.8522 mL | 1.7044 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA